Sedivention Raises €2.9M for Innovative Obesity Treatment

German medtech innovator Sedivention has successfully closed a €2.9 million seed funding round, signaling a significant advancement in its mission to revolutionize obesity treatment. The capital infusion was spearheaded by bmp Ventures and supported by the IBG funds, with crucial participation from the strategic investment arm of a global medtech firm, High-Tech Gründerfonds (HTGF), and Cambridge Ventures, alongside contributions from angel investors. This funding is earmarked to propel the company through critical stages of product development and initial clinical validation.

Sedivention is pioneering a groundbreaking, single-session outpatient therapy designed to address obesity, a complex metabolic disorder projected to impact over a billion individuals worldwide in the coming years. Current interventions, ranging from bariatric surgery to long-term pharmacological treatments, often present significant drawbacks including invasiveness, substantial costs, and the necessity for continuous patient management. Sedivention's approach aims to circumvent these limitations by offering a less burdensome, yet highly effective, alternative.

At the core of Sedivention's innovation is a sophisticated cryoablation technique delivered via a specialized balloon catheter, administered in a procedure akin to gastroscopy. This minimally invasive method precisely targets and interrupts hunger-signaling pathways within the vagus nerve. By addressing the physiological underpinnings of appetite regulation, the therapy seeks to induce sustained appetite reduction without the need for surgical implants, ongoing medication, or extensive recovery periods, marking a paradigm shift in chronic disease management.

The company has already demonstrated the viability of its concept through the development and testing of a functional prototype. The newly acquired funds will be instrumental in refining the product, initiating a first-in-human clinical study to gather essential safety and efficacy data, and preparing the groundwork for regulatory submissions and eventual market launch. This strategic funding positions Sedivention to move decisively towards transforming the treatment landscape for obesity.

Obesity represents a substantial and growing global health challenge, with associated healthcare costs escalating annually. The market for obesity treatments is expanding rapidly, driven by increasing prevalence and a growing demand for less invasive and more sustainable solutions. Sedivention's focus on a one-time, outpatient intervention addresses a clear unmet need, potentially offering a scalable and accessible option that could significantly reduce the long-term burden on patients and healthcare systems alike. The company's ambition is to establish its cryoablation therapy as a viable, less invasive alternative to current surgical procedures.